Accueil » Communiqués de presse » Valbiotis announces the large success of the REVERSE-IT international multicentric Phase II/III clinical study on TOTUM•63: proven efficacy on the main risk factor of developing type 2 diabetes.
Les communiqués de presse
22May2023
Valbiotis announces the large success of the REVERSE-IT international multicentric Phase II/III clinical study on TOTUM•63: proven efficacy on the main risk factor of developing type 2 diabetes.
We use cookies to guarantee the best experience on our site, to make statistics, to offer you third party services such as video like Youtube, social networks sharing. By clicking on validate and closing this banner, you accept the deposit of cookies.AcceptRefuseMore information
You can revoke your consent at any time by using the "Revoke Consent" button.Revoke consent
